Zoledronic Acid for Treatment of Low Bone Mineral Density in Patients with Beta Thalassemia Major

about

Zoledronic Acid for Treatment of Low Bone Mineral Density in Patients with Beta Thalassemia Major

Item

http://www.wikidata.org/entity/Q58125050

description

scientific article published on 27 March 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Zoledronic Acid for Treatment ...... ts with Beta Thalassemia Major

@en

Zoledronic Acid for Treatment ...... ts with Beta Thalassemia Major

@nl

type

Item

label

Zoledronic Acid for Treatment ...... ts with Beta Thalassemia Major

@en

Zoledronic Acid for Treatment ...... ts with Beta Thalassemia Major

@nl

prefLabel

Zoledronic Acid for Treatment ...... ts with Beta Thalassemia Major

@en

Zoledronic Acid for Treatment ...... ts with Beta Thalassemia Major

@nl

P1476

Zoledronic Acid for Treatment ...... ts with Beta Thalassemia Major

@en

P2093

H Pati

http://www.w3.org/2001/XMLSchema#string

Jagdish Chandra

http://www.w3.org/2001/XMLSchema#string

Nikhil Tandon

http://www.w3.org/2001/XMLSchema#string

Renu Saxena

http://www.w3.org/2001/XMLSchema#string

Tulika Seth

http://www.w3.org/2001/XMLSchema#string

V P Choudhry

http://www.w3.org/2001/XMLSchema#string

P2860

New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia.

Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature.

Evaluation of osteopathy in thalassemia by bone mineral densitometry and biochemical indices.

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.

Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy.

Quantitative computed tomography is unreliable for measurement of bone mineral density in inadequately chelated adolescent patients with β-thalassemia major: a case-control study.

Bisphosphonates in the treatment of thalassemia-induced osteoporosis.

Complications of beta-thalassemia major in North America.

Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma.

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.

P2888

s12288-018-0953-x

P304

648-652

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12288-018-0953-X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rahul Naithani

P577

2018-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30369735

http://www.w3.org/2001/XMLSchema#string

P921

hematology

P932

6186220

http://www.w3.org/2001/XMLSchema#string